This is your employment contract http://apetube.in.net/ apetube com Francois Venter of the University of the Witwatersrand, who is the lead clinical researcher for the South African leg of the trial, says that countries such as relatively wealthy South Africa may be able to provide TDF, which has been recommended for first-line treatment in the country since 2010. But "in a country like Malawi, let's say they use TDF for a year and then don't have the money and the alternative is d4T [at 30mg] and we do not have the data for the 20mg dosage, the reality is that, in many countries, if this study fails or shuts down, people are going to [continue to] be on 30mg d4T, rather than a safer dose of d4T".